Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma

A.O.U. Città della Salute e della Scienza118 enrolled

Overview

Treatments-related cardiotoxicity is a critical issue in long term lymphoma survivors, particularly at young age, and its early identification is important to prevent clinically relevant cardiac events. Complete echocardiographic assessment including 2-dimension global longitudinal strain (2D-GLS), seems to be an effective tools in detecting preclinical systolic changes to the cardiac function even when the ejection fraction is preserved. The aim of Cardiocare study is to investigate early detection of subclinical chemo and radiation-induced changes in left ventricular function using 2D-GLS.

Study Type

OBSERVATIONAL

Enrollment

118

Conditions

Lymphoma, Non-Hodgkin Hodgkin Lymphoma Toxicity, Cardiac

Eligibility

Sex: ALLMin age: 19 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>18 years * Diagnosis of Hodgkin Disease (HD) or Primary Mediastinal B-cell lymphoma (PMBCL) or diffuse large B-cell lymphoma (DLBCL) * Disease requiring treatment with anthracycline containing regimen only (cohort A) or anthracycline containing regimen followed by mediastinal radiotherapy (cohort B) * Written informed consent Exclusion Criteria: * Age \> 70 years * Unable to perform anthracyline containing regimen * Previous treatment with mediastinal radiotherapy * Kidney failure (defined as creatinine x2 UNL) or liver failure (defined as AST and ALT x2 UNL) * ECOG PS \> 2 * Echocardiographic acoustic windows not suitable for strain evaluation * Any other conditions or situations preventing patients to sign informed consent

Outcomes

Primary Outcomes

Left ventricular ejection fraction (LVEF)

Left ventricular ejection fraction measured by echocardiography

Time frame: Baseline, Change of LVEF from Baseline at 4/6 month (end of chemotherapy), Change of LVEF from Baseline at 6/8 months (end of radiotherapy - if applicable), Change of LVEF from Baseline at 9/11 months (3 months after treatment completion)

Global Longitudinal Strain (GLS)

Global Longitudinal Strain measured by strain-rate echocardiography

Time frame: Baseline, Change of GLS from Baseline at 4/6 month (end of chemotherapy), Change of GLS from Baseline at 6/8 months (end of radiotherapy - if applicable), Change of GLS from Baseline at 9/11 months (3 months after treatment completion)

Secondary Outcomes

Anthracycline cumulative dose

Time frame: 4/6 month after baseline (end of chemotherapy)

T troponin

T troponin rate

Time frame: Baseline, Before each chemotherapy administration, 4/6 month after baseline (end of chemotherapy), 6/8 months after baseline (end of radiotherapy - if applicable), 9/11 months after baseline (3 months after treatment completion)